Abstract
Liver metastases from neuroendocrine tumor (NET) can be treated by transarterial embolization (TAE) or transarterial chemoembolization (TACE). The goal of TAE and TACE is to reduce blood flow to the tumor resulting in tumor ischemia and necrosis. In this retrospective study, the effectiveness and safety of TAE–TACE in the treatment of liver metastases in patients with NET was compared. Thirty patients with a histologically confirmed gastro-entero-pancreatic NET with liver metastases were retrospectively investigated. Seventeen patients underwent TAE, while 13 patients underwent TACE. Tumor response, degree of devascularization in treated lesions, and progression free survival (PFS) were evaluated in the whole population and then separately in TAE and TACE subgroups. In all patients treated with TAE and TACE, there was a significant size reduction of lesions as compared to baseline. Per lesion reduction was 2.2 ± 1.4 versus 3.3 ± 1.5 cm for TAE (p < 0.001) and 2.2 ± 1.5 versus 3.4 ± 1.7 cm for TACE (p < 0.001). In the whole population, the median PFS for all patients was 36 months (16.2–55.7 CI), without significant difference between TAE and TACE. In no patient did adverse events grade 3 and 4 as well as TAE/TACE-related death occurred, while the post-embolization syndrome occurred in 41 % of patients treated with TAE and 61 % of those treated with TACE. TAE and TACE are both effective in NET patients with liver metastases. TAE should be preferred to TACE in light of its similar anti-tumor effects and slightly better toxicity profile.
Similar content being viewed by others
Abbreviations
- NET:
-
Neuroendocrine tumor
- TAE:
-
Transarterial embolization
- TACE:
-
Transarterial chemoembolization
- HPF:
-
High power fields
- MDCT:
-
Contrast-enhanced multidetector-row computed tomography
- PFS:
-
Progression free survival
References
E. Solcia et al., Natural history, clinicopathologic classification and prognosis of gastric ECL cell tumors. Yale J. Biol. Med. 71(3–4), 285–290 (1998)
A. Faggiano et al., Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: the NET management study. J. Endocrinol. Invest. 35(9), 817–823 (2012)
H. Chen et al., Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J. Am. Coll. Surg. 187(1), 88–92 (1998).; discussion 92–93
J.M. Sarmiento et al., Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J. Am. Coll. Surg. 197(1), 29–37 (2003)
D.S. Klimstra et al., The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39(6), 707–712 (2010)
J. Iwazawa et al., Transarterial chemoembolization with miriplatin-lipiodol emulsion for neuroendocrine metastases of the liver. World J Radiol 2(12), 468–471 (2010)
J.G. Touzios et al., Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann. Surg. 241(5), 776–783 (2005).; discussion 783–785
A. Roche et al., Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur. Radiol. 13(1), 136–140 (2003)
C.G. Moertel et al., The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann. Intern. Med. 120(4), 302–309 (1994)
G.M. Mavligit et al., Durable hepatic tumor regression after arterial chemoembolization-infusion in patients with islet cell carcinoma of the pancreas metastatic to the liver. Cancer 72(2), 375–380 (1993)
C. Loewe et al., Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am. J. Roentgenol. 180(5), 1379–1384 (2003)
S. Del Prete et al., Percutaneous ethanol injection of autonomous thyroid nodules with a volume larger than 40 ml: three years of follow-up. Clin. Radiol. 56(11), 895–901 (2001)
J. Qian, Interventional therapies of unresectable liver metastases. J. Cancer Res. Clin. Oncol. 137(12), 1763–1772 (2011)
H. Bergsma et al., Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract. Res. Clin. Gastroenterol. 26(6), 867–881 (2012)
H. Rajekar, K. Bogammana, R.S. Stubbs, Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment. Int. J. Hepatol. 2011, 404916 (2011)
J. Nazario, S. Gupta, Transarterial liver-directed therapies of neuroendocrine hepatic metastases. Semin. Oncol. 37(2), 118–126 (2010)
F.T. Bosman, World Health Organization, International Agency for Research on Cancer, WHO classification of tumours of the digestive system, World Health Organization Classification of Tumours, 4th edn. (International Agency for Research on Cancer, Lyon, 2010), p. 417
R. Syha et al., Hepatocellular carcinoma: initial tumour response after short-term and long-interval chemoembolization with drug-eluting beads using modified RECIST. Eur. J. Gastroenterol. Hepatol. 24(11), 1325–1332 (2012)
T.J. Vogl et al., Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur. J. Radiol. 72(3), 517–528 (2009)
A.S. Ho et al., Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am. J. Roentgenol. 188(5), 1201–1207 (2007)
A.T. Ruutiainen et al., Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J. Vasc. Interv. Radiol. 18(7), 847–855 (2007)
P.P. Kamat et al., Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases. Cardiovasc. Intervent. Radiol. 31(2), 299–307 (2008)
S. Gupta et al., Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 9(4), 261–267 (2003)
S.C. Pitt et al., Hepatic neuroendocrine metastases: chemo- or bland embolization? J. Gastrointest. Surg. 12(11), 1951–1960 (2008)
Acknowledgments
This study did not receive any specific Grant from any funding agency in the public, commercial or not-for-profit sector. We are extremely grateful to all subjects who took part in these studies and the research teams who collected the data. All the authors contributed equally to the preparation of this article.
Conflict of interest
All the authors declare that there are no conflict of interest that could be perceived as prejudicing the impartiality of the data reported.
Author information
Authors and Affiliations
Corresponding author
Additional information
On the behalf of the Multidisciplinary Group for NeuroEndocrine Tumors of Naples.
Francesco Fiore and Michela Del Prete contributed equally to the paper.
Rights and permissions
About this article
Cite this article
Fiore, F., Del Prete, M., Franco, R. et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine 47, 177–182 (2014). https://doi.org/10.1007/s12020-013-0130-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-013-0130-9